The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive

NCT ID: NCT02677207

Last Updated: 2020-05-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-02-29
• Study Completion Date: 2017-07-31

Brief Summary

To evaluate the effects of the nicotinic allosteric modulator JNJ-39393406 on psychometric performance and residual depressive symptoms in patients who have been diagnosed with unipolar and bipolar depression but currently DO NOT meet criteria for an episode of Major Depression or Manic Episode.

Detailed Description

To evaluate the effects of the nicotinic allosteric modulator JNJ-39393406 on psychometric performance and residual depressive symptoms in patients who have been diagnosed with unipolar and bipolar depression but currently DO NOT meet criteria for an episode of Major Depression or Manic Episode.

Hypothesis: Allosteric modulation of the a7nAChR with JNJ-39393406 improves psychometric performance and residual depressive symptoms in patients with unipolar major depression disorder (MDD) or bipolar depression (BPD).

Outcome measurements:

• BACS
• MADRS
• BNSS
• CGI-S- BP,
• Questionnaire on smoking urges (QSU) and time to the first cigarette after waking up in the morning,
• Readiness for discharge scale.

Conditions

Depression

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

JNJ-39393406

2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.

Group Type: EXPERIMENTAL

JNJ-39393406

Intervention Type: DRUG

JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial

Placebo

2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial

Interventions

JNJ-39393406

JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial

Intervention Type: DRUG

Placebo

JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Meet DSM V criteria for history of MDD or BPD by MINI.

2. Between 18-50 years of age, male or female subjects of any race, smokers and non-smokers.

3. Able to provide informed consent. All participant patients must have signed an informed consent document indicating they understand the purpose of the study and the procedures required for the study and are willing to participate by complying with the study procedures and restrictions.

4. Have a MADRS ≥ 10 and ≤ 34 and an YMRS < 7.

5. In the opinion of the investigator, basic education and severity of symptoms (psychotic, negative, manic, agitation, depression) do not prevent the patient from attending to the cognitive tasks.

6. In the opinion of the investigator the patient can be safely treated with no more than 2 psychotropic medications as background therapy (SOS for agitation and sleeping medication are allowed in addition to the 2 psychotropics).

7. The background psychotropic(s) that will be continued through-out the 2 week trial must have been started at least 2 weeks prior to the baseline day at doses allowed by the local regulations and no changes in dose have been made during this pre-baseline 2 week period.

8. Inpatients or out-patients at the discretion of the investigator (If outpatients the Readiness for Discharge Scale has to be administered at baseline and at each visit.)

Exclusion Criteria

1. Women of child bearing potential who do not practice contraception.

2. Psychosis, florid manic or major depressive episode during the 4 weeks preceding baseline day or current psychosis.

3. Patients on more than 2 psychotropic (hypnotics for sleep and occasional SOS for agitation do not count).

4. Smokes more than 40 cigarettes per day.

5. Unstable medical disease (malignancy, poorly controlled diabetes, or cardiomyopathy, serious pulmonary disease, kidney disease, impaired liver functioning. Particular attention should be given to exclude patients with ischemic heart disease).

6. Has a clinically significant abnormal 12-lead electrocardiogram (ECG) at Screening Visit 1 as determined by the Investigator.

7. At significant risk of committing suicide, or in the opinion of the Investigator, currently is at imminent risk of suicide or harming others.

8. Patients with a current DSM-V substance or alcohol dependence.

9. Concurrent delirium, mental retardation, drug-induced psychosis, or history of stroke, brain degenerative disorders and brain trauma.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

Sponsor Role: collaborator

Tangent Data

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Davidson, M.D.

Role: PRINCIPAL_INVESTIGATOR

Principal Investigator

Locations

Clinical Psychiatric Hospital

Codru, , Moldova

S.C. Stefi-Dent Srl

Botoșani, , Romania

Hospital of Psychiatry and Neurology

Brasov, , Romania

Spit. Clinic de Urgenta Militar "Dr. Stefan Odobleja"

Craiova, , Romania

Countries

Moldova; Romania

Other Identifiers

JNJ-DEP

Identifier Type: -

Identifier Source: org_study_id